Treatment of prediabetes

doi:10.4239/wjd.v6.i12.1207

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14108)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

1169

WORD

398

HTML

7840

Figures (1-7)

305

Tables (1-1)

146

Sum=9858

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

528

Download

1403

Sum=1931

Publishing Process of This Article

Item

Count

Browse

1135

Download

1184

Sum=2319

Sep 25, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (52)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Sep 25, 2015; 6(12): 1207-1222
Published online Sep 25, 2015. doi: 10.4239/wjd.v6.i12.1207

Full Size Figure Download Figure

Figure 7 Effect of physiologic (A) and pharmacologic (B) doses of glucagon-like peptide-1 on insulin secretion in normal glucose tolerance individuals and in subjects with type 2 diabetes mellitus. GLP-1: Glucagon-like peptide-1.

Citation: Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222
URL: https://www.wjgnet.com/1948-9358/full/v6/i12/1207.htm
DOI: https://dx.doi.org/10.4239/wjd.v6.i12.1207